Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Rating of “Buy” by Analysts

Delcath Systems, Inc. (NASDAQ:DCTH) has been given an average recommendation of “Buy” by the six ratings firms that are covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $19.83.

A number of research analysts recently weighed in on the stock. HC Wainwright lifted their price objective on shares of Delcath Systems from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, May 15th. Craig Hallum assumed coverage on shares of Delcath Systems in a research note on Friday, June 28th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, Stephens assumed coverage on shares of Delcath Systems in a research note on Tuesday, May 14th. They issued an “overweight” rating and a $25.00 price objective for the company.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of DCTH. Levin Capital Strategies L.P. lifted its holdings in shares of Delcath Systems by 22.5% during the 4th quarter. Levin Capital Strategies L.P. now owns 49,000 shares of the company’s stock worth $204,000 after acquiring an additional 9,000 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of Delcath Systems during the 4th quarter worth $962,000. Legato Capital Management LLC bought a new stake in shares of Delcath Systems during the 2nd quarter worth $966,000. Worth Venture Partners LLC bought a new stake in shares of Delcath Systems during the 4th quarter worth $1,224,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Delcath Systems by 31.0% during the 1st quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock worth $3,261,000 after acquiring an additional 161,678 shares during the last quarter. 61.12% of the stock is owned by institutional investors.

Delcath Systems Stock Down 0.9 %

Shares of DCTH stock opened at $8.12 on Friday. The company has a 50 day moving average of $7.80 and a 200-day moving average of $5.94. Delcath Systems has a 12-month low of $2.25 and a 12-month high of $9.18. The firm has a market cap of $225.65 million, a P/E ratio of -3.06 and a beta of 0.64.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.43). Delcath Systems had a negative net margin of 1,080.72% and a negative return on equity of 290.07%. The company had revenue of $3.14 million during the quarter, compared to analyst estimates of $3.70 million. As a group, equities analysts expect that Delcath Systems will post -1.31 EPS for the current year.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.